

ASCO DIRECT CURRENT UPDATE 2017

24-25 November 2017 | Crowne Plaza Hotel, Jeddah, KSA

2017
ASCO
ANNUAL MEETING
Making a Difference in Cancer Care *WITH YOU*



SCIENTIFIC PROGRAM

ORGANIZED BY:



LICENSED BY:



SPONSORED BY:



SCIENTIFIC PROGRAM

DAY 1 - FRIDAY, 24 NOVEMBER 2017

Session 1: IMMUNO-ONCOLOGY / DEVELOPMENT OF THERAPEUTICS

Moderators: Dr. Ashwaq Al Olayan | Prof. Khaled Al Kattan

13:30 - 14:00	Registration	
14:00 - 14:20	Precision Medicine in the Era of Immuno-Oncology	Dr. Aung Naing
14:20 - 14:40	Biomarker of Immunotherapy	Dr. Joud Hajjar
14:40 - 15:00	Future Direction of Immuno-Oncology	Dr. Aung Naing



Bristol-Myers Squibb

Mining for Treatment Options in Recurrent/Metastatic Head and Neck Cancer

Dr. Arif Adnan Shawkat
 15:00 - 15:30

15:30 - 16:00

COFFEE BREAK

Session 2: BREAST CANCER

Moderators: Dr. Ahmad Al Faraj |

16:00 - 16:20	Update in Management of ER Positive Advanced Breast Cancer <ul style="list-style-type: none"> Abemaciclib for HR-positive/ HER2-Negative Metastatic Breast Cancer (Abstract 1000) Update on CDK 416 inhibitors 	Dr. Abdul Rahman Alshehri
16:20 - 16:40	Immunotherapy in Breast Cancer <ul style="list-style-type: none"> Neoadjuvant Pembrolizumab for HER2-Negative Breast Cancer (Abstract 506) Durvalumab and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics. 	Dr. Khalid Alsaleh

SCIENTIFIC PROGRAM

DAY 1 - FRIDAY, 24 NOVEMBER 2017

16:40 - 17:00	Update in Management of Early Breast Cancer <ul style="list-style-type: none"> • Adjuvant Pertuzumab plus Trastuzumab for HER2-Positive Early Disease APHINITY trial (abstract LBA500) • Olaparib for Patients with HER2-Negative BRCA-Mutated Disease OlympiAD trial (abstract LBA4) 	Dr. Mervat Mahrous
17:00 - 17:20	Bone Health and Cancer <ul style="list-style-type: none"> • Role of Bone-Modifying Agents in Metastatic Breast Cancer Update • Evaluating the impact of bone-targeted agents in the era of novel androgen targeted therapy for metastatic castration-resistant prostate cancer 	Dr. Medhat Faris



Roche Sponsored Session
17:20

19:00

GALA DINNER

SCIENTIFIC PROGRAM

DAY 2 - SATURDAY, 25 NOVEMBER 2017



Session 3: LUNG CANCER Moderators: Dr. Ahmed Abdelwarith Dr. Ahmed Bamousa		
08:30 - 09:00	Registration	
09:00 - 09:20	Stage II-III Lung Cancer <ul style="list-style-type: none"> ADJUVANT: Phase III Trial Evaluating Gefitinib vs Vinorelbine/ Cisplatin in Completely Resected Stage II-III A (N1-N2) NSCLC with EGFR Activating Mutations abstract 8500 » Adjuvant Durulumab in Lung Cancer 	Dr. Jawaher Ansari
09:20 - 09:40	Targeted Therapy <ul style="list-style-type: none"> ALEX: Alectinib vs Crizotinib as First-Line Therapy in Patients with ALK + NSCLC: Abstract LBA9008 ARCHER 1050: First-Line Dacomitinib vs Gefitinib in EGFR-Mutant Advanced NSCLC: Abstract LBA9007 AURA-3: CNS Response to Osimertinib in EGFR T790M+ Advanced NSCLC: Abstract 9005 » Osimertinib First Line Study 	Dr. Hamed AlHusaini
09:40 - 10:00	Immunotherapy in Metastatic Lung Cancer <ul style="list-style-type: none"> Immunotherapy in Metastatic Lung Cancer Progression After the Next Line of Therapy (PFS2) and Updated OS Among Patients with Advanced NSCLC and PD-L1 TPS $\geq 50\%$ enrolled in KEYNOTE-024 Atezolizumab Treatment Beyond Disease Progression in Advanced NSCLC: Results from the Randomized Ph III OAK Study First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G 	Dr. Abdullah AlTwairqi
10:00 - 10:20	New Development in Radiation Therapy <ul style="list-style-type: none"> New Radiation Technique in Early Non-Small Cell Lung Cancer » Pro-cons of choice of ablative modality - Part of the Oligometastatic NSCLC Session. 	Dr. Ameen Alomair
10:20 - 10:40	Q & A, Panel Discussion	
10:40 - 11:10	COFFEE BREAK	

SCIENTIFIC PROGRAM

DAY 2 - SATURDAY, 25 NOVEMBER 2017



Session 4: GI

Moderators: Dr. Azzam Khankan | Dr. Abdullah AlZahrani

11:10 - 11:30	Pancreas <ul style="list-style-type: none"> Randomized Phase 2 Study of PEGHPH20 Plus nab-Paclitaxel/ Gemcitabine (PAG) vs. nab-Paclitaxel/ Gemcitabine (AG) in Patients with Untreated, Metastatic Pancreatic Ductal Adenocarcinoma 	Dr. Ahmad Al Zahrani
11:30 - 11:50	Colon Cancer <ul style="list-style-type: none"> Prospective Pooled Analysis of Six Phase III Trials Investigating Duration of Adjuvant Oxaliplatin-Based Therapy (3 vs. 6 months) for Patients with Stage III Colon Cancer: The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration 	Dr. Fahad IbnShamsah
11:50 - 12:10	Hepatocellular Carcinoma <ul style="list-style-type: none"> Phase III Multicenter Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) vs. Sorafenib in Locally Advanced Hepatocellular Carcinoma: The SIRveNIB Study 	Dr. Jamal Zekri
12:10 - 12:30	Q & A, Panel Discussion	

12:30 - 13:30

LUNCH

Session 5: GU / SARCOMA / OTHER MALIGNANCIES

Moderator: Dr. Mohammad Algarni | Dr. Emad Tashkandi

13:30 - 13:50	Sarcoma <ul style="list-style-type: none"> Alliance A091401: A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma Multicenter Phase II Study of Pembrolizumab in Advanced Soft Tissue and Bone Sarcomas: Final Results of SARCO28 and Biomarker Analyses Multi-institutional European single-arm phase II trial of Pazopanib in advance malignant/dedifferentiated Solitary Fibrous Tumors (SFT). A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups Study 	Dr. Ashwaq Al Olayan
---------------	---	----------------------

SCIENTIFIC PROGRAM

DAY 2 - SATURDAY, 25 NOVEMBER 2017

13:50 - 14:10	<p>Management of Bladder Cancer</p> <ul style="list-style-type: none"> • Updated Survival Analysis From KEYNOTE-045: Phase 3, Open-Label Study of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine in Recurrent, Advanced Urothelial Cancer » IMvigor211: A Phase III Randomized Study Examining Atezolizumab vs. Chemotherapy for Platinum-Treated Advanced Urothelial Carcinoma 	Dr. Abdullah Al Sharm
14:10 - 14:30	<p>Prostate & Kidney Cancer</p> <ul style="list-style-type: none"> • LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. • Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476) » First Line Nivolumab + Ipilimumab in metastatic renal cell carcinoma 	Dr. Mubarak Al Mansour
14:30 - 14:50	<p>Management of Merkel Cell Tumor</p> <ul style="list-style-type: none"> • Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy • First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study • Avelumab (MSB0010718C; anti-PD- L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial 	Dr. Ali AlFakeeh
14:50 - 15:10	Q & A, Panel Discussion	
15:10	ADJOURNMENT	